What is it about?
New review of the beta-lactam/beta-lactamase inhibitor, ceftolozane/tazobactam
Featured Image
Why is it important?
A recent review of current data suggest that ceftolozane–tazobactam is a promising carbapenem-sparing alternative agent for the treatment of cUTIs and cIAIs, including those caused by ESBL-producing Enterobacteriaceae and MDR P. aeruginosa.
Read the Original
This page is a summary of: Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections, Therapeutics and Clinical Risk Management, May 2016, Dove Medical Press,
DOI: 10.2147/tcrm.s83844.
You can read the full text:
Contributors
The following have contributed to this page
